𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of lonidamine plus radiotherapy in the treatment of brain metastases

✍ Scribed by David J. Stewart; Libni Eapen; Andre Girard; Shailendra Verma; Paul Genest; William K. Evans

Publisher
Springer US
Year
1993
Tongue
English
Weight
264 KB
Volume
15
Category
Article
ISSN
0167-594X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The combined use of radiation therapy an
The combined use of radiation therapy and lonidamine in the treatment of brain metastases
✍ Lisa M. DeAngelis; Violante E. Currie; Jae-Ho Kim; George Krol; Maureen A. O'Heh πŸ“‚ Article πŸ“… 1989 πŸ› Springer US 🌐 English βš– 492 KB

Lonidamine is an indazole carboxylic acid that has been shown to be synergistic with radiotherapy (RT) in tissue culture and animal models. Clinical experience has shown that lonidamine is well-tolerated, and appears to potentiate the activity of conventional chemotherapy in the treatment of brain m

Temozolomide plus thalidomide in patient
Temozolomide plus thalidomide in patients with brain metastases from melanoma : A Phase II study
✍ Wen-Jen Hwu; Eric Lis; Jennifer H. Menell; Katherine S. Panageas; Lynne A. Lamb; πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 98 KB

## Abstract ## BACKGROUND Temozolomide plus thalidomide is a promising oral combination regimen for the treatment of metastatic melanoma. The current Phase II study examined the efficacy and safety of this combination in chemotherapy‐naive patients with brain metastases. ## METHODS Patients with

Randomized trial of radiotherapy versus
Randomized trial of radiotherapy versus radiotherapy plus metronidazole for the treatment metastatic cancer to brain
✍ Harmon J Eyre; Joel D Ohlsen; Jess Frank; Albert F LoBuglio; Joseph D McCracken; πŸ“‚ Article πŸ“… 1984 πŸ› Springer US 🌐 English βš– 358 KB

One hundred sixteen eligible patients with metastatic cancer to the brain were randomized to receive either radiotherapy 3000 rad/!0 fractions (treatment l) or the same radiotherapy plus metronidazole 6 gm/m 2 (treatment 2). One hundred eleven patients were either fully or partially evaluable. The r